

Express Mail No.: EL 477 036 798 US

Attachment to Paper #7

| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | | | | ATTY. DOCKET NO. 10271-047 | APPLICATION NO. 09/996,288 | |
|--|----|-----------------|----------|---|-------------------------------|-------------------------------|
| | | | | APPLICANT Young et al. | | |
| | | | | FILING DATE November 28, 2001 | GROUP 1641-1648 | |
| U.S. PATENT DOCUMENTS | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS SUBCLASS | FILING DATE IF APPROPRIATE |
| SBC | AA | 4,526,938 | 7/2/85 | Churchill et al. | | |
| | AB | 4,880,078 | 11/14/89 | Inoue et al. | | |
| | AC | 5,128,326 | 7/7/92 | Balazs et al. | | |
| | AD | 5,290,540 | 3/1/94 | Prince et al. | | |
| | AE | 5,679,377 | 10/21/97 | Bernstein et al. | | |
| | AF | 5,824,307 | 10/20/98 | Johnson | | |
| | AG | 5,855,913 | 1/5/99 | Hanes et al. | | |
| | AH | 5,874,064 | 2/23/99 | Edwards et al. | | |
| | AI | 5,912,015 | 6/15/99 | Bernstein et al. | | |
| | AJ | 5,916,597 | 6/29/99 | Lee et al. | | |
| | AK | 5,934,272 | 8/10/99 | Lloyd et al. | | |
| | AL | 5,985,309 | 11/16/99 | Edwards et al. | | |
| | AM | 5,985,320 | 11/16/99 | Edwards et al. | | |
| | AN | 5,989,463 | 11/23/99 | Tracy et al. | | |
| | AO | 6,019,968 | 2/1/00 | Platz et al. | | |
| | AP | 09/168,130 | | "Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus" | | 9/21/98 |
| | AQ | 09/865,400 | | "Epitope-Based Vaccine for Respiratory Syncytial Virus F-Protein" | | 5/25/01 |
| | AR | 09/848,300 | | "Combination Therapy of Respiratory Diseases using Antibodies" | | 5/3/01 |
| | AS | 09/046,377 | | "Combination Therapy of Respiratory Diseases Using Antibodies and Anti-Inflammatory Agents" | | 5/3/01 |
| | AT | 09/797,760 | | "Methods of Enhancing Activity of Vaccines and Vaccine Compositions" | | 3/2/01 |
| | AU | 09/796,848 | | "High Potency Recombinant Antibodies and Methods for Producing Them" | | 3/1/01 |
| | AV | 09/781,052 | | "Antibody Gene Therapy with Adeno-Associated Viral Vectors" | | 2/8/01 |
| | AW | 09/771,415 | | "Ultra High Affinity Neutralizing Antibodies" | | 1/26/01 |
| | AX | 09/186,252 | | "High Potency Recombinant Antibodies and Methods for Producing Them" | | 3/1/00 |
| | AY | 09/168,426 | | "High Potency Recombinant Antibodies and Methods for Producing Them" | | 1/27/00 |
| | AZ | 5,811,524 | 0/22/98 | Brams et al. | | |
| | BA | 5,840,298 | 11/24/98 | Brams et al. | | |
| | BB | 5,866,125 | 2/2/99 | Brams et al. | | |

AP-AY
not
in
conformance
SBC
5/7/2004

| | | | | | | | |
|-----|----|---------------|---------|--------------|--|--|--|
| SBC | BC | 5,955,364 | 9/21/99 | Brams et al. | | | |
| ↓ | BD | 5,958,765 | 9/28/99 | Brams et al. | | | |
| ↓ | BE | 2002 0001 798 | 1/3/02 | Brams et al. | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|-----|----|-----------------|----------|---------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| SBC | BF | WO 91/05548 | 5/2/91 | PCT | | | | |
| | BG | WO 92/19244 | 11/12/92 | PCT | | | | |
| | BH | WO 96/20698 | 7/11/96 | PCT | | | | |
| | BI | WO 97/34631 | 9/25/97 | PCT | | | | |
| | BJ | WO 97/32572 | 9/12/97 | PCT | | | | |
| | BK | WO 97/44013 | 11/27/97 | PCT | | | | |
| | BL | WO 98/31346 | 7/23/98 | PCT | | | | |
| | BM | WO 99/15154 | 4/01/99 | PCT | | | | |
| | BN | WO 99/20253 | 4/29/99 | PCT | | | | |
| ↓ | BO | WO 99/66903 | 12/29/99 | PCT | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|-----|----|---|
| SBC | BP | Abman et al., 1988, "Role of Respiratory Syncytial Virus in Early Hospitalizations for Respiratory Distress of Young Infants With Cystic Fibrosis", J Pediatr. 113(5):826-30. |
| | BQ | American Academy of Pediatrics Committee on Infectious Diseases: Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection. Pediatrics. 1993 Sep;92(3):501-4. |
| | BR | Beeler et al., 1989, "Neutralization Epitopes of the F Glycoprotein of Respiratory Syncytial Virus: Effect of Mutation Upon Fusion Function", J Virol. 63(7):2941-50. |
| | BS | Bentley et al., 1980, "Human immunoglobulin variable region genes-- DNA Sequences of Two V Kappa Genes and a Pseudogene", Nature 288: 5194-5198 |
| | BT | Cleek et al., 1997, "Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application" Pro. Int'l Symp. Control. Rel Bioact. Mater. 24: 853-854 |
| | BU | Evans, A.S., 1989, Viral Infections of Humans, Epidemiology and Control, 3 rd ed., 525-44 |
| | BV | Falsey et al., 1991, "Noninfluenza Respiratory Virus Infection in Long-Term Care Facilities", Infect Control Hosp Epidemiol. 12(10):602-8.. |
| | BW | Feigen et al., 1987, Textbook of Pediatric Infectious Diseases, WB Saunders, Philadelphia, pp. 1653-1675 |
| | BX | Garvie et al., 1980, "Outbreak of Respiratory Syncytial Virus Infection in the Elderly", Br Med J. 281(6250):1253-4. |
| | BY | Glezen et al., 1981, "Risk of Respiratory Syncytial Virus Infection for Infants From Low-Income Families in Relationship to Age, Sex, Ethnic Group, and Maternal Antibody Level", J Pediatr. 98(5):708-15. |
| | BZ | Groothuis et al., 1988, "Respiratory Syncytial Virus Infection in Children with Bronchopulmonary Dysplasia", Pediatrics. 82(2):199-203. |
| | CA | Groothuis et al., 1993, "Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-risk Infants and Young Children", The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 329(21):1524-30. |
| | CB | Hall et al., 1979, "Neonatal Respiratory Syncytial Virus Infection", N Engl J Med. 300(8):393-6. |
| | CC | Hall, C.B., 1993, Respiratory Syncytial: What We Know Now", Contemp. Pediatrics, 10: 92-110. |
| | CD | Hemming et al., 1985, "Studies of Passive Immunotherapy for Infections of Respiratory Syncytial Virus in the Respiratory Tract of a Primate Model", J Infect Dis. 152(5):1083-7. |
| ↓ | CE | Henderson et al., 1979, "Respiratory-Syncytial-Virus Infections, Reinfections and Immunity. A Prospective, Longitudinal Study in Young Children", N Engl J Med. 300(10):530-4. |

| | | |
|-----|----|--|
| SBC | CF | Hertz et al., 1989, "Respiratory Syncytial Virus-Induced Acute Lung Injury in Adult Patients With Bone Marrow Transplants: a Clinical Approach and Review of the Literature", <i>Medicine (Baltimore)</i> . 68(5):269-81. |
| | CG | Howard et al., 1989, "Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits", <i>J Neurosurg</i> . 71(1):105-12. |
| | CH | Johnson et al., 1987, "The G Glycoprotein of Human Respiratory Syncytial Viruses of Subgroups A and B: Extensive Sequence Divergence Between Antigenically Related Proteins", <i>Proc Natl Acad Sci U S A</i> . 84(16):5625-9. |
| | CI | Johnson et al., 1987, "Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent <i>In Vitro</i> and <i>In Vivo</i> Activity Against Respiratory Syncytial Virus", <i>J Infect Dis</i> . 176(5):1215-24. |
| | CJ | Kapikian et al., 1969, "An Epidemiologic Study of Altered Clinical Reactivity to Respiratory Syncytial (RS) Virus Infection in Children Previously Vaccinated With an Inactivated RS Virus Vaccine", <i>Am J Epidemiol</i> . 89(4):405-21. |
| | CK | Kim et al., 1969, "Respiratory Syncytial Virus Disease in Infants Despite Prior Administration of Antigenic Inactivated Vaccine", <i>Am J Epidemiol</i> . 89(4):422-34. |
| | CL | Lam et al., 1997, "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery", <i>Proc. Int'l. Symp. Control Rel. Bioact. Mater</i> . 24:759-760. |
| | CM | Lamprecht et al., 1976, "Role of Maternal Antibody in Pneumonia and Bronchiolitis Due to Respiratory Syncytial Virus", <i>J Infect Dis</i> . 134(3):211-7. |
| | CN | Levy et al., 1985, "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-release Diphosphonate", <i>Science</i> . 228(4696):190-2. |
| | CO | MacDonald et al., 1982, "Respiratory Syncytial Viral Infection in Infants With Congenital Heart Disease", <i>N Engl J Med</i> . 307(7):397-400. |
| | CP | Morell et al., eds, 1986, <i>Clinical Use of Intravenous Immunoglobulins</i> , Academic Press, London, pp. 285-94. |
| | CQ | Murphy et al., 1991, "Effect of Passive Antibody on the Immune Response of Cotton Rats to Purified F and G HG Glycoproteins of Respiratory Syncytial Virus (RSV)", <i>Vaccine</i> . 9(3):185-9. |
| | CR | Murphy et al., 1988, "Passive Transfer of Respiratory Syncytial Virus (RSV) Antiserum Suppresses The Immune Response to the RSV Fusion (F) and Large (G) Glycoproteins Expressed By Recombinant Vaccinia Viruses", <i>J Virol</i> . 62(10):3907-10. |
| | CS | Murphy and Hall, 1994, "An Update on Approaches to the Development of Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) Vaccines", <i>Virus Res</i> . 32(1):13-36. |
| | CT | Navas et al., 1992, "Improved Outcome of Respiratory Syncytial Virus Infection in a High-Risk Hospitalized Population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada", <i>J Pediatr</i> . 121(3):348-54. |
| | CU | Ning et al., 1996, "Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained Release Gel", <i>Radiotherapy and Oncology</i> 39: 179-89. |
| | CV | Ogra et al., 1988, "Respiratory Syncytial Virus Infection and the Immunocompromised Host", <i>Pediatr Infect Dis J</i> . 1988 Apr;7(4):246-9. |
| | CW | Palivizumab et al., 1998, "A Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-Risk Infants", <i>The Impact-RSV Study Group. Pediatrics</i> . 102(3 Pt 1):531-7. |
| | CX | Pohl et al., 1992, "Respiratory Syncytial Virus Infections in Pediatric Liver Transplant Recipients", <i>J Infect Dis</i> . 165(1):166-9. |
| | CY | Press et al., 1970, "The Amino Acid Sequences of the Fd Fragments of Two Human Gamma-1 Heavy chains", <i>Biochem J</i> . 117(4):641-60. |
| | CZ | Prince et al., 1985, "Immunoprophylaxis and Immunotherapy of Respiratory Syncytial Virus Infection in the Cotton rat", <i>Virus Res</i> . 3(3):193-206. |
| | DA | Prince et al., 1983, "Mechanisms of Immunity to Respiratory Syncytial Virus in Cotton Rats", <i>Infect Immun</i> . 42(1):81-7. |
| | DB | Prince et al., 1990, "Mechanism of Antibody-mediated Viral Clearance in Immunotherapy of Respiratory Syncytial Virus Infection of Cotton Rats", <i>J Virol</i> . 64(6):3091-2. |
| | DC | Prince et al., 1985, "Quantitative Aspects of Passive Immunity to Respiratory Syncytial Virus Infection in Infant Cotton Rats", <i>J Virol</i> . 55(3):517-20. |
| | DD | Ruuskanen et al., 1993, "Respiratory syncytial virus", <i>Curr Probl Pediatr</i> . 23(2):50-79. |
| N | DE | Saez-Llorens et al., 1998, "Safety and Pharmacokinetics of an Intramuscular Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants and Infants with Bronchopulmonary Dysplasia", <i>Pediatric Infect Dis J</i> . 17:787091. |

| | | |
|---|----|--|
| SBC | DF | Saudek et al., 1989, "A Preliminary Trial of the Pprogrammable Implantable Medication System for Insulin Delivery. N Engl J Med. 321(9):574-9. |
| | DG | Sefton, 1987, "Implantable Pumps", CRC Crit. Ref. Biomed. Eng. 14:20 |
| | DH | Smith et al., 1991, "A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection", N Engl J Med. 325(1):24-9. |
| | DI | Song et al., 1995, "Antibody Mediated Lung Targeting of Long-Circulating Emulsions", PDA Journal of Pharmaceutical Science & Technology 50: 372-97 |
| | DJ | Subramanian et al., "Safety, Tolerance and Pharmacokinetics of a Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants and Infants with Bronchopulmonary Dysplasia", Pediatric Infect Dis J. 17:110-115 (1998) |
| ✓ | DK | Walsh et al., 1987, "Immunization with Glycoprotein Subunits of Respiratory Syncytial Virus to Protect Cotton Rats Against Viral Infection", J Infect Dis. 155(6):1198-204. |
| | | |
| EXAMINER <i>Stacy B. Chen</i> | | DATE CONSIDERED <i>July 11, 2003</i> |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | |



| | | |
|---|----------------------------------|----------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY DOCKET NO. | APPLICATION NO |
| | 10271-047 | 09/996,288 |
| | APPLICANT Young et al. | |
| | FILING DATE | GROUP |
| | November 28, 2001 | 1648 |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|----|-----------------|----------|---------------|-------|----------|----------------------------|
| SBC | DL | 5,939,068 | 8/17/99 | Brams et al. | | | |
| | DU | 6,537,809 | 3/25/03 | Brams | | | |
| | DV | 6,096,551 | 8/1/00 | Barbas et al. | | | |
| | DW | 5,693,762 | 12/2/97 | Queen et al. | | | |
| | DX | 5,585,089 | 12/17/96 | Queen et al. | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|-----|----|-----------------|---------|---------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| SBC | DY | WO 00/29584 | 5/25/00 | PCT/us | | | | |
| SBC | DM | WO 96/05229 | 2/22/96 | us | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|-----|----|--|
| SBC | DN | Hacking et al., 2002, "Respiratory syncytial virus - viral biology and the host response," J. Infection 45:18-24 |
| | DO | Heard et al., 1999, "Two neutralizing human RSV antibodies: cloning, expression, and characterization," Mol. Med. 5:35-45 |
| | DP | Landry et al., "Evaluation of reconstituted lophilized palivizumab given intravenously at 15 and 30 mg/kg," Poster Session, Tuesday, Infect. Dis. 166A: 969 (1999) |
| | DQ | Saez-Llorens et al., 1997, "Phase I/II open label multi dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children," Abstracts in Non HIV virology, ICAAC Toronto |
| | DR | Subramanian et al., 1997, "Randomized double blind placebo controlled dose escalation trial of a humanized respiratory syncytial virus monoclonal antibody in high risk infants," Poster session infect. dis. 130A:768 |
| | DS | Sorbera et al., 1998, "Palivizumab," Drugs of the Future 23:970-976 |
| | DT | Sorbera et al., 1998, "Palivizumab," Drugs Data Report 20:702-703 |
| | DZ | Anderson et al., 1985, "Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay," J. Clin. Microbiol. 22:1050-1052 |
| | EA | Boulianne et al., 1984, "Production of functional chimaeric mouse/human antibody," Nature 312(5995):643-646 |
| | EB | Carson et al., 1986, "Human lymphocyte hybridomas and monoclonal antibodies," Adv. Immunol. 38:275-311 |
| | EC | Conrad et al., 1987, "Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic," Pediatr. Infect. Dis. J. 6(2):152-158 |
| | ED | Cruse et al., 1995, Illustrated Dictionary of Immunology, Boca Raton: CRC Press, pp. 18-19 |
| | EE | Dorland's Illustrated Medical Dictionary, 1994, 28 th ed., Philadelphia: WB Saunders p. 874 |
| | EF | Duenas et al., 1996, "In vitro immunization of naïve human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display," Blackwell Science Limited, pp. 1-7 |
| | EG | Duenas et al., 1996, "Selection of phage displayed antibodies based on kinetic constants," 33(3):279-285 |
| | EH | Everitt et al., 1996, "The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers," J. Infect. Dis. |
| | EI | Foote et al., 1995, "Kinetic and affinity limits on antibodies produced during immune response," Proc. Nat'l Acad. Science USA 92:1254-1256 |
| | EJ | Foote et al., 1991, "Kinetic maturation of an immune response," Nature vol. 352 |

| | | |
|------------|----|--|
| <i>SBC</i> | EK | Glaser et al., 1992, "Antibody engineering by codon-based mutagenesis in a filamentous phage vector system," J. Immunol. 149:3903-3913 |
| | EL | Greenspan et al., 1999, Nature Biotechnology 7:936-937 |
| | EM | Groves et al., 1987, "Production of an ovine monoclonal antibody to testosterone by an interspecies fusion," Hybridoma 6(1):71-76 |
| | EN | Hall et al., 1985, "Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease," JAMA 254(21):3047-3051 |
| | EO | Hall et al., 1983, "Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study," N. Engl. J. Med. 308(24):1443-1447 |
| | EP | Hall et al., 1975, "Nosocomial respiratory syncytial virus infections," N. Engl. J. Med. 293(26):1343-1346 |
| | EQ | Haynes et al., 2002, "Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection," J. Virol. 76(14):6873-6881 |
| | ER | Johnson et al., 1999, "A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19," J. Infect. Dis. 180(1):35-40 |
| | ES | Karlsson et al., 1997, "Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors," J Immunol. Meth. |
| | ET | Knappik et al., 2000, "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides," Academic Press, pp. 57-86 |
| | EU | Liu et al., 1987, "Expression of mouse:human immunoglobulin heavy-chain cDNA in lymphoid cells," Gene 54(1):33-40 |
| | EV | LoBuglio et al., 1989, "Mouse/human chimeric monoclonal antibody in man: kinetics and immune response," Proc. Natl. Acad. Sci. USA 86(11):4220-4224 |
| | EW | Morrison et al., 1985, "Transfectomas provide novel chimeric antibodies," Science 229(4719):1202-1207 |
| | EX | Morrison et al., 1984, "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. USA 81(21):6851-6855 |
| | EY | Myszka et al., 1999, "Survey of the 1998 optical biosensor literature," J. Mol. Recog. |
| | EZ | Newman et al., 1992, "'Primitization' of recombinant antibodies for immunotherapy of human diseases: A Macaque/Human chimeric antibody against human CD4," 10:1455-1460 |
| | FA | Prince et al., 1996, "Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid," J. Infect. Dis. pp.598-608 |
| | FB | Raman et al., 1992, "Diffusion-limited rates for monoclonal antibody binding to cytochrome," Biochem. |
| | FC | Roost et al., 1995, "Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity," PNAS USA 92:1257-1261 |
| | FD | Rosok et al., 1995, "A combinatorial library strategy for the rapid humanization of anticarcinoma BR 96 Fab," JBC 271(27):22611-22618 |
| | FE | Rudikoff et al., 1982, "Single amino acid substitution altering antigen-binding specificity," Proc. Natl. Acad. Sci. USA 79(6):1979-1983 |
| | FF | Sahagan et al., 1986, "A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen," J. Immunol. 137(3):1066-1074 |
| | FG | Schier et al., 1996, "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," J. Mol. Biol. 263(4):551-567 |
| | FH | Steplewski et al., 1988, "Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity," Proc. Natl. Acad. Sci. USA 85(13):4852-4856 |
| | FI | Sun et al., 1987, "Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A," Proc. Natl. Acad. Sci. USA 84(1):214-218 |
| | FJ | Takeda et al., 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature 314(6010):452-454 |
| | FK | Talwar et al., 1976, "Isoimmunization against human chorionic gonadotropin with conjugates of processed beta-subunit of the hormone and tetanus toxoid," Proc. Natl. Acad. Sci. USA 73(1):218-222 |
| | FL | van Wyke et al., 1985, "Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus," Virology 143(2):569-582 |
| | FM | Wald et al., 1988, "In re ribavirin: a case of premature adjudication?" J. Pediatr. 112(1):154-158 |
| | FN | Wright et al., 1982, "Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children," Infect. Immun. 37(1):397-400 |
| | FO | Wu et al., 1998, "Stepwise in vitro affinity maturation of Vitaxin, an avb-specific humanized mAb," PNAS 95:6037-6042 |
| ✓ | FP | Geneseq Database, Accession no: AAW70933, entry date Oct. 1998 from patent no FR2758331-A1 of Bourgeois et al. |

EXAMINER *Stacy B. Chen*DATE CONSIDERED *May 7, 2004*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.

10271-047

APPLICATION NO

09/996,288

APPLICANT

Young et al.

FILING DATE

November 28, 2001

GROUP

1648

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|-----------------|---------|--------------|-------|----------|-------------------------------|
| SBC | DL | 5,939,068 | 8/17/99 | Brams et al. | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|-----|----|-----------------|---------|---------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| SBC | DM | WO 96/05229 | 2/22/96 | PCT | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|-----|----|--|
| SBC | DN | Hacking et al., 2002, "Respiratory syncytial virus - viral biology and the host response," J. Infection 45:18-24 |
| | DO | Heard et al., 1999, "Two neutralizing human RSV antibodies: cloning, expression, and characterization," Mol. Med. 5:35-45 |
| | DP | Landry et al., "Evaluation of reconstituted lophilized palivizumab given intravenously at 15 and 30 mg/kg," Poster Session, Tuesday, Infect. Dis. 166A: 969 |
| | DQ | Saez-Llorens et al., 1997, "Phase I/II open label multi dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children," Abstracts in Non HIV virology, ICAAC Toronto |
| | DR | Subramanian et al., 1997, "Randomized double blind placebo controlled dose escalation trial of a humanized respiratory syncytial virus monoclonal antibody in high risk infants," Poster session infect. dis. 130A:768 |
| | DS | Sorbera et al., 1998, "Palivizumab," Drugs of the Future 23:970-976 |
| ↓ | DT | Sorbera et al., 1998, "Palivizumab," Drugs Data Report 20:702-703 |

EXAMINER

Stacy B. Chen

DATE CONSIDERED

May 7, 2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.